Tweet
Why Amgen, Inc.'s Kyprolis FOCUS Failure Is a Big Deal NASDAQ Amgen 's Kyprolis has passed multiple clinical trials, but the failure today will overshadow the rest. That's because the only thing that really matters to cancer patients is survival. Does the drug help the patient live longer? Living longer without the disease ... UPDATE 2-Amgen drug fails to improve survival in multiple myeloma trialReuters Amgen Announces Trial Setback, RecallLos Angeles Business Journal Amgen Blood Cancer Drug Fails Primary Endpoint In Late-Stage StudyRTT News Wall Street Journal -Baltimore Sun all 30 news articles » |
More...